CN111278857A - 抗c5抗体治疗患有膜增生性肾小球肾炎的患者的剂量和施用 - Google Patents

抗c5抗体治疗患有膜增生性肾小球肾炎的患者的剂量和施用 Download PDF

Info

Publication number
CN111278857A
CN111278857A CN201880065034.5A CN201880065034A CN111278857A CN 111278857 A CN111278857 A CN 111278857A CN 201880065034 A CN201880065034 A CN 201880065034A CN 111278857 A CN111278857 A CN 111278857A
Authority
CN
China
Prior art keywords
antibody
antigen
binding fragment
week
ser
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201880065034.5A
Other languages
English (en)
Chinese (zh)
Inventor
G·雷穆齐
P·鲁格内内蒂
X·高
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Alexion Pharmaceuticals Inc
Original Assignee
Alexion Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alexion Pharmaceuticals Inc filed Critical Alexion Pharmaceuticals Inc
Publication of CN111278857A publication Critical patent/CN111278857A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biophysics (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Dermatology (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN201880065034.5A 2017-10-04 2018-10-02 抗c5抗体治疗患有膜增生性肾小球肾炎的患者的剂量和施用 Pending CN111278857A (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201762568060P 2017-10-04 2017-10-04
US62/568,060 2017-10-04
US201862652615P 2018-04-04 2018-04-04
US62/652,615 2018-04-04
PCT/US2018/053976 WO2019070714A1 (en) 2017-10-04 2018-10-02 ASSAY AND ADMINISTRATION OF ANTI-C5 ANTIBODIES FOR THE TREATMENT OF PATIENTS WITH MEMBRANOPROLIFERATIVE GLOMERULONEPHRIPT

Publications (1)

Publication Number Publication Date
CN111278857A true CN111278857A (zh) 2020-06-12

Family

ID=64051671

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201880065034.5A Pending CN111278857A (zh) 2017-10-04 2018-10-02 抗c5抗体治疗患有膜增生性肾小球肾炎的患者的剂量和施用

Country Status (11)

Country Link
US (2) US20200262897A1 (https=)
EP (2) EP4424324A3 (https=)
JP (2) JP2020536097A (https=)
KR (1) KR20200059279A (https=)
CN (1) CN111278857A (https=)
AU (1) AU2018345625A1 (https=)
BR (1) BR112020006692A2 (https=)
CA (1) CA3078362A1 (https=)
CO (1) CO2020004831A2 (https=)
MX (1) MX2020003619A (https=)
WO (1) WO2019070714A1 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025031279A1 (zh) * 2023-08-04 2025-02-13 上海览屹医药科技有限公司 一种高浓度高稳定性的抗体制剂及其制备方法

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR106018A1 (es) 2015-08-26 2017-12-06 Achillion Pharmaceuticals Inc Compuestos de arilo, heteroarilo y heterocíclicos para el tratamiento de trastornos médicos
WO2017035409A1 (en) 2015-08-26 2017-03-02 Achillion Pharmaceuticals, Inc. Aryl, heteroaryl, and heterocyclic compounds for treatment of immune and inflammatory disorders
WO2017035405A1 (en) 2015-08-26 2017-03-02 Achillion Pharmaceuticals, Inc. Amino compounds for treatment of immune and inflammatory disorders
WO2017035401A1 (en) 2015-08-26 2017-03-02 Achillion Pharmaceuticals, Inc. Amide compounds for treatment of immune and inflammatory disorders
EP3589287B1 (en) 2017-03-01 2022-09-14 Achillion Pharmaceuticals, Inc. Macrocyclic compounds for treatment of medical disorders
CN110603252A (zh) 2017-03-01 2019-12-20 艾其林医药公司 用于治疗医学障碍的芳基、杂芳基和杂环药物化合物
WO2018160891A1 (en) 2017-03-01 2018-09-07 Achillion Pharmaceutical, Inc. Pharmaceutical compounds for treatment of medical disorders
US20190038623A1 (en) 2017-08-02 2019-02-07 Achillion Pharmaceuticals, Inc. Therapeutic regimens for treatment of paroxysmal nocturnal hemoglobinuria
US20210215714A1 (en) * 2018-05-25 2021-07-15 Achillion Pharmaceuticals, Inc. Complement alternative pathway-associated nephropathy biomarkers
US11814363B2 (en) 2018-09-06 2023-11-14 Achillion Pharmaceuticals, Inc. Morphic forms of danicopan
WO2020051532A2 (en) 2018-09-06 2020-03-12 Achillion Pharmaceuticals, Inc. Macrocyclic compounds for the treatment of medical disorders
BR112021005506A2 (pt) 2018-09-25 2021-06-15 Achillion Pharmaceuticals, Inc. formas mórficas de inibidores de fator complementar d
KR20210104071A (ko) 2018-12-17 2021-08-24 아칠리온 파르마세우티칼스 인코포레이티드 보체 매개 장애의 치료를 위한 표적 투약
WO2020198062A1 (en) 2019-03-22 2020-10-01 Achillion Pharmaceuticals, Inc. Pharmaceutical compounds for the treatment of complement mediated disorders
EP4007605A4 (en) * 2019-08-01 2023-08-16 Momenta Pharmaceuticals, Inc. ANTI-FCRN ANTIBODIES AND METHODS OF USE THEREOF
WO2025257877A1 (ja) * 2024-06-10 2025-12-18 株式会社I’mbesideyou 情報処理システム及び情報処理方法

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6074642A (en) 1994-05-02 2000-06-13 Alexion Pharmaceuticals, Inc. Use of antibodies specific to human complement component C5 for the treatment of glomerulonephritis
LT2894165T (lt) * 2008-11-10 2023-03-10 Alexion Pharmaceuticals, Inc. Būdai ir kompozicijos, skirti su komplementu susijusių sutrikimų gydymui
NZ631007A (en) 2014-03-07 2015-10-30 Alexion Pharma Inc Anti-c5 antibodies having improved pharmacokinetics
EP3313437A1 (en) * 2015-06-26 2018-05-02 Alexion Pharmaceuticals, Inc. A method for treating a patient in compliance with vaccination with eculizumab or an eculizumab variant
NZ789212A (en) * 2016-06-17 2026-02-27 Chugai Pharmaceutical Co Ltd Anti-c5 antibodies and methods of use

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025031279A1 (zh) * 2023-08-04 2025-02-13 上海览屹医药科技有限公司 一种高浓度高稳定性的抗体制剂及其制备方法

Also Published As

Publication number Publication date
JP2020536097A (ja) 2020-12-10
US20240025975A1 (en) 2024-01-25
EP3692064A1 (en) 2020-08-12
EP4424324A2 (en) 2024-09-04
KR20200059279A (ko) 2020-05-28
MX2020003619A (es) 2020-10-28
EP4424324A3 (en) 2024-11-06
BR112020006692A2 (pt) 2020-10-06
CO2020004831A2 (es) 2020-05-29
JP2023101717A (ja) 2023-07-21
AU2018345625A1 (en) 2020-04-16
CA3078362A1 (en) 2019-04-11
US20200262897A1 (en) 2020-08-20
WO2019070714A1 (en) 2019-04-11

Similar Documents

Publication Publication Date Title
US20240025975A1 (en) Administration of anti-c5 antibodies for treatment of patients with membranoproliferative glomerulonephritis
JP7579227B2 (ja) 瘻孔を伴うクローン病の治療用ベドリズマブ
JP7577542B2 (ja) 小児患者における非典型溶血性尿毒症症候群（ａＨＵＳ）の治療のための抗Ｃ５抗体の用量および投与
JP2024133611A (ja) 抗ｐｄ－１抗体および別の抗癌剤の組合せを用いる肺癌の処置法
JP2018109056A (ja) Ｉｌ−４ｒアンタゴニストを投与することにより喘息を処置又は予防するための方法
CN117838856A (zh) 用于治疗非典型溶血性尿毒综合征(ahus)的抗c5抗体的剂量和施用
CN112996561A (zh) 用于治疗阵发性睡眠性血红蛋白尿症(pnh)的抗c5抗体的皮下剂量和施用
US20260070973A1 (en) suPAR and Prediction and Treatment of Acute Kidney Injury
JP2023515675A (ja) Ｐｄ－１アンタゴニスト、ｃｔｌａ４アンタゴニストおよびレンバチニブまたはその薬学的に許容される塩の組合せを用いる癌を治療する方法
JP7589045B2 (ja) リゲリズマブを使用して慢性特発性蕁麻疹を治療する方法
US20240092881A1 (en) Methods of treating complement mediated thrombotic microangiopathy using an anti-c5 antibody
JP2026026191A (ja) 造血幹細胞移植関連血栓性微小血管症（ｈｓｃｔ－ｔｍａ）を処置するための抗ｃ５抗体の用量及び投与
US20230009657A1 (en) Methods of treating lupus nephritis using interleukin-17 (il-17) antagonists
KR20250029919A (ko) 갈렉틴-9를 억제하는 항체를 사용한 혈액학적 악성종양의 치료
WO2023134787A2 (zh) 抗pd-1抗体和抗vegf抗体组合在治疗肝细胞癌中的用途
CN116261569A (zh) 用于治疗包括狼疮性肾炎（LN）和/或IgA肾病（IgAN）的C5介导的肾小球肾炎（GN）的抗C5抗体的剂量和施用
JP2024517796A (ja) 抗ｂａｆｆｒ抗体を使用するループス腎炎の治療
JP7734673B2 (ja) 抗ｃ５抗体を使用して妊娠関連非典型溶血性尿毒症症候群を治療する方法
HK40110798A (en) Methods of treating complement mediated thrombotic microangiopathy using an anti-c5 antibody
WO2025166118A1 (en) Dosage and administration of anti-c5 antibodies for treating iga nephropathy (igan)
CN118055761A (zh) 包含tigit拮抗剂、pd-1拮抗剂和化学治疗剂的治疗组合
CN121219312A (zh) 剂量方案
CN117940161A (zh) 伊奈利珠单抗及其在治疗或预防IgG4相关疾病中的使用方法

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20200612

WD01 Invention patent application deemed withdrawn after publication